Cited 0 times in Scipus Cited Count

Efficacy of high-dose chemotherapy and autologous stem cell transplantation in patients with relapsed medulloblastoma: a report on the Korean Society for Pediatric Neuro-Oncology (KSPNO)-S-053 study.

DC Field Value Language
dc.contributor.authorPark, JE-
dc.contributor.authorKang, J-
dc.contributor.authorYoo, KH-
dc.contributor.authorSung, KW-
dc.contributor.authorKoo, HH-
dc.contributor.authorLim, DH-
dc.contributor.authorShin, HJ-
dc.contributor.authorKang, HJ-
dc.contributor.authorPark, KD-
dc.contributor.authorShin, HY-
dc.contributor.authorKim, IH-
dc.contributor.authorCho, BK-
dc.contributor.authorIm, HJ-
dc.contributor.authorSeo, JJ-
dc.contributor.authorPark, HJ-
dc.contributor.authorPark, BK-
dc.contributor.authorAhn, HS-
dc.date.accessioned2011-05-19T05:15:03Z-
dc.date.available2011-05-19T05:15:03Z-
dc.date.issued2010-
dc.identifier.issn1011-8934-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/2651-
dc.description.abstractThe efficacy and toxicity of high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) were investigated for improving the outcomes of patients with relapsed medulloblastoma. A total of 15 patients with relapsed medulloblastoma were enrolled in the KSPNO-S-053 study from May 2005 to May 2007. All patients received approximately 4 cycles of salvage chemotherapy after relapse. Thirteen underwent HDCT/ASCT; CTE and CM regimen were employed for the first HDCT (HDCT1) and second HDCT (HDCT2), respectively, and 7 underwent HDCT2. One transplant related mortality (TRM) due to veno-occlusive disease (VOD) occurred during HDCT1 but HDCT2 was tolerable with no further TRM. The 3-yr overall survival probability and event-free survival rates +/-95% confidence intervals (CI) were 33.3+/-12.2% and 26.7% +/-11.4%, respectively. When analysis was confined to only patients who had a complete response (CR) or partial response (PR) prior to HDCT, the probability of 3-yr overall survival rates +/-95% CI was 40.0+/-15.5%. No patients with stable disease (SD) or progressive disease (PD) survived. Survival rates from protocol KSPNO-S-053 are encouraging and show that tumor status prior to HDCT/ASCT is an important factor to consider for improving survival rates of patients with relapsed medulloblastoma.-
dc.language.isoen-
dc.subject.MESHAdolescent-
dc.subject.MESHCerebellar Neoplasms-
dc.subject.MESHChild-
dc.subject.MESHChild, Preschool-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHematopoietic Stem Cell Transplantation-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMedulloblastoma-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHSalvage Therapy-
dc.subject.MESHTransplantation, Autologous-
dc.subject.MESHYoung Adult-
dc.titleEfficacy of high-dose chemotherapy and autologous stem cell transplantation in patients with relapsed medulloblastoma: a report on the Korean Society for Pediatric Neuro-Oncology (KSPNO)-S-053 study.-
dc.typeArticle-
dc.identifier.pmid20676326-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908784/-
dc.contributor.affiliatedAuthor박, 준은-
dc.type.localJournal Papers-
dc.identifier.doi10.3346/jkms.2010.25.8.1160-
dc.citation.titleJournal of Korean medical science-
dc.citation.volume25-
dc.citation.number8-
dc.citation.date2010-
dc.citation.startPage1160-
dc.citation.endPage1166-
dc.identifier.bibliographicCitationJournal of Korean medical science, 25(8). : 1160-1166, 2010-
dc.identifier.eissn1598-6357-
dc.relation.journalidJ010118934-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pediatrics & Adolescent Medicine
Files in This Item:
20676326.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse